Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Bladder Dysfunction Reports
Published in: Current Bladder Dysfunction Reports 3/2011

01-09-2011

Use of Injectable Urethral Bulking Agents in the Management of Stress Urinary Incontinence

Authors: Aisha Khalali Taylor, Elodi Dielubanza, John Hairston

Published in: Current Bladder Dysfunction Reports | Issue 3/2011

Login to get access

Abstract

The use of injectable bulking agents is a well-established approach to management of patients with stress urinary incontinence (SUI). No single bulking agent to date has been shown to be superior or consistently durable in the literature. Novel therapeutic strategies, including the use of injectable, muscle-derived stem cell therapy, have shown promising results in investigational stages. Urethral bulking agent therapy can be helpful in the early management of men with SUI following radical prostatectomy, and in women with SUI due to intrinsic sphincter deficiency, urethral hypermobility, or in the setting of failed midurethral sling placement. Despite their widespread use historically, biocompatible agents have been supplanted in recent years by synthetic agents secondary to their potentially improved durability and nonimmunogenic profiles.
Literature
1.
Kerr LA. Bulking agents in the treatment of stress urinary incontinence: history, outcomes, patient populations, and reimbursement profile. Rev Urol. 2005;7 Suppl 1:S3–S11.PubMed
2.
Sandhu JS. Treatment options for male stress urinary incontinence. Nat Rev Urol. 2010;7(4):222–8.PubMedCrossRef
3.
Fultz NH, Burgio K, Diokno AC, Kinchen KS, Obenchain R, Bump RC. Burden of stress urinary incontinence for community-dwelling women. Am J Obstet Gynecol. 2003;189(5):1275–82.PubMedCrossRef
4.
Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004;63(3):461–5.PubMedCrossRef
5.
van der Vaart CH, de Leeuw JR, Roovers JP, Heintz AP. The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int. 2002;90(6):544–9.PubMedCrossRef
6.
Borgermann C, Kaufmann A, Sperling H, Stohrer M, Rubben H. The treatment of stress incontinence in men: part 2 of a series of articles on incontinence. Dtsch Arztebl Int. 2010;107(27):484–91.PubMed
7.
Keegan PE, Atiemo K, Cody J, McClinton S, Pickard R. Periurethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev. 2007;3:CD003881.PubMed
8.
Dmochowski RR, Appell RA. Injectable agents in the treatment of stress urinary incontinence in women: where are we now? Urology. 2000;56(6 Suppl 1):32–40.PubMedCrossRef
9.
Kershen RT, Dmochowski RR, Appell RA. Beyond collagen: injectable therapies for the treatment of female stress urinary incontinence in the new millennium. Urol Clin North Am. 2002;29(3):559–74.PubMedCrossRef
10.
Appell RA WJ. Campbell-Walsh urology. In: Editor-in-chief, Wein AJ; Kavoussi LR, et al., editors. 3. Saunders, Philadelphia; 2007.
11.
Schulz JA, Nager CW, Stanton SL, Baessler K. Bulking agents for stress urinary incontinence: short-term results and complications in a randomized comparison of periurethral and transurethral injections. Int Urogynecol J Pelvic Floor Dysfunct. 2004;15(4):261–5.PubMed
12.
Gonzalez de Garibay AS, Castillo Jimeno JM, Villanueva Perez I, Figuerido Garmendía E, Vigata López MJ, Sebastían Borruel JL. Treatment of urinary stress incontinence using paraurethral injection of autologous fat. Arch Esp Urol. 1991;44(5):595–600.PubMed
13.
Lee PE, Kung RC, Drutz HP. Periurethral autologous fat injection as treatment for female stress urinary incontinence: a randomized double-blind controlled trial. J Urol. 2001;165(1):153–8.PubMedCrossRef
14.
Bartynski J, Marion MS, Wang TD. Histopathologic evaluation of adipose autografts in a rabbit ear model. Otolaryngol Head Neck Surg. 1990;102(4):314–21.PubMed
15.
16.
Remacle M, Marbaix E. Collagen implants in the human larynx. Pathological examinations of two cases. Arch Otorhinolaryngol. 1988;245(4):203–9.PubMedCrossRef
17.
Sharifi-Aghdas F. Surgical management of stress urinary incontinence. Urol J. 2005;2(4):175–82.PubMed
18.
Walters MD, Daneshgari F. Surgical management of stress urinary incontinence. Clin Obstet Gynecol. 2004;47(1):93–103.PubMedCrossRef
19.
Faerber GJ. Endoscopic collagen injection therapy in elderly women with type I stress urinary incontinence. J Urol. 1996;155(2):512–4.PubMedCrossRef
20.
Bano F, Barrington JW, Dyer R. Comparison between porcine dermal implant (Permacol) and silicone injection (Macroplastique) for urodynamic stress incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16(2):147–50. discussion 150.PubMedCrossRef
21.
Berg S. Polytef augmentation urethroplasty. Correction of surgically incurable urinary incontinence by injection technique. Arch Surg. 1973;107(3):379–81.PubMed
22.
McKinney CD, Gaffey MJ, Gillenwater JY. Bladder outlet obstruction after multiple periurethral polytetrafluoroethylene injections. J Urol. 1995;153(1):149–51.PubMedCrossRef
23.
Lopez AE, Padron OF, Patsias G, Politano VA. Transurethral polytetrafluoroethylene injection in female patients with urinary continence. J Urol. 1993;150(3):856–8.PubMed
24.
Buckley J, Lingham K, Meddings R, et al. Injectable silicone microparticles for female stress incontinence. Proceedings of the British Association of Urologic Surgeons Bristol, United Kingdom; 1995.
25.
• Ghoniem G, Corcos J, Comiter C, Westney OL, Herschorn S. Durability of urethral bulking agent injection for female stress urinary incontinence: 2-year multicenter study results. J Urol. 2010;183(4):1444–9. For urethral injection of Macroplastique (silicone), substantial durable results were sustained during 2 years, with 84% of patients maintaining significant Stamey grade improvement from the 12-month assessment. PubMedCrossRef
26.
Pannek J, Brands FH, Senge T. Particle migration after transurethral injection of carbon coated beads for stress urinary incontinence. J Urol. 2001;166(4):1350–3.PubMedCrossRef
27.
Ritts RE. Re: particle migration after transurethral injection of carbon coated beads for stress urinary incontinence. J Urol. 2002;167(4):1804–5.PubMedCrossRef
28.
Lightner D, Calvosa C, Andersen R, Klimberg I, Brito CG, Snyder J, et al. A new injectable bulking agent for treatment of stress urinary incontinence: results of a multicenter, randomized, controlled, double-blind study of Durasphere. Urology. 2001;58(1):12–5.PubMedCrossRef
29.
Chrouser KL, Fick F, Goel A, Itano NB, Sweat SD, Lightner DJ. Carbon coated zirconium beads in beta-glucan gel and bovine glutaraldehyde cross-linked collagen injections for intrinsic sphincter deficiency: continence and satisfaction after extended follow-up. J Urol. 2004;171(3):1152–5.PubMedCrossRef
30.
Dmochowski R. Multicenter randomized controlled study to evaluate Uryx urethral bulking agent in treating female stress urinary incontinence. Proceedings of the International Continence Society, 32nd Annual Meeting. 2002.
31.
Administration USFaD: Uryx? Urethral Bulking Agent-P030030: Summary of safety and effectiveness data. 2004.
32.
Kuhn A, Stadlmayr W, Sohail A, Monga A. Long-term results and patients’ satisfaction after transurethral ethylene vinyl alcohol (Tegress) injections: a two-centre study. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(4):503–7.PubMedCrossRef
33.
Hurtado E, McCrery R, Appell R. The safety and efficacy of ethylene vinyl alcohol copolymer as an intra-urethral bulking agent in women with intrinsic urethral deficiency. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(8):86973.
34.
Mayer RD, Dmochowski RR, Appell RA, Sand PK, Klimberg IW, Jacoby K, et al. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology. 2007;69(5):876–80.PubMedCrossRef
35.
Lai HH, Hurtado EA, Appell RA. Large urethral prolapse formation after calcium hydroxylapatite (Coaptite) injection. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(9):1315–7.PubMedCrossRef
36.
Swami S, Batista JE, Abrams P. Collagen for female genuine stress incontinence after a minimum 2-year follow-up. Br J Urol. 1997;80(5):757–61.PubMed
37.
Steele AC, Kohli N, Karram MM. Periurethral collagen injection for stress incontinence with and without urethral hypermobility. Obstet Gynecol. 2000;95(3):327–31.PubMedCrossRef
38.
Herschorn S, Radomski SB. Collagen injections for genuine stress urinary incontinence: patient selection and durability. Int Urogynecol J Pelvic Floor Dysfunct. 1997;8(1):18–24.PubMedCrossRef
39.
Lightner D, Rovner E, Corcos J, Payne C, Brubaker L, Drutz H, et al. Randomized controlled multisite trial of injected bulking agents for women with intrinsic sphincter deficiency: mid-urethral injection of Zuidex via the Implacer versus proximal urethral injection of Contigen cystoscopically. Urology. 2009;74(4):771–5.PubMedCrossRef
40.
• Lightner DJ, Fox J, Klingele C. Cystoscopic injections of dextranomer hyaluronic acid into proximal urethra for urethral incompetence: efficacy and adverse outcomes. Urology. 2010;75(6):1310–4. This study highlighted a high rate of complications associated with cystoscopically injected dextranomer hyaluronic acid at the bladder neck, suggesting that this approach should be abandoned. PubMedCrossRef
41.
Strasser H, Tiefenthaler M, Steinlechner M, Bartsch G, Konwalinka G. Urinary incontinence in the elderly and age-dependent apoptosis of rhabdosphincter cells. Lancet. 1999;354(9182):918–9.PubMedCrossRef
42.
Strasser H, Tiefenthaler M, Steinlechner M, Eder I, Bartsch G, Konwalinka G. Age dependent apoptosis and loss of rhabdosphincter cells. J Urol. 2000;164(5):1781–5.PubMedCrossRef
43.
Digesu GA, Robinson D, Cardozo L, Khullar V. Three-dimensional ultrasound of the urethral sphincter predicts continence surgery outcome. Neurourol Urodyn. 2009;28(1):90–4.PubMedCrossRef
44.
Kershen RT, Fefer SD, Atala A. Tissue-engineered therapies for the treatment of urinary incontinence and vesicoureteral reflux. World J Urol. 2000;18(1):51–5.PubMedCrossRef
45.
Proano AR, Medrano A, Garrido G, Mazza O. Muscle-derived stem cell therapy for stress urinary incontinence. Actas Urol Esp. 2010;34(1):15–23.PubMedCrossRef
46.
Bent AE. Treatment of intrinsic sphincter deficiency using autologous ear chondrocytes as a bulking agent. Neurourol Urodyn. 2001;20(2):157–65.PubMedCrossRef
47.
Strasser H, Marksteiner R, Margreiter E, Pinggera GM, Mitterberger M, Frauscher F, et al. Autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: a randomised controlled trial. Lancet. 2007;369(9580):2179–86.PubMedCrossRef
48.
Mitterberger M, Marksteiner R, Margreiter E, Pinggera GM, Colleselli D, Frauscher F, et al. Autologous myoblasts and fibroblasts for female stress incontinence: a 1-year follow-up in 123 patients. BJU Int. 2007;100(5):1081–5.PubMed
49.
Mitterberger M, Pinggera GM, Marksteiner R, Margreiter E, Fussenegger M, Frauscher F, et al. Adult stem cell therapy of female stress urinary incontinence. Eur Urol. 2008;53(1):169–75.PubMedCrossRef
50.
Carr LK, Steele D, Steele S, Wagner D, Pruchnic R, Jankowski R, et al. 1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(6):881–3.PubMedCrossRef
51.
Lee HN, Lee YS, Han JY, Jeong JY, Choo MS, Lee KS. Transurethral injection of bulking agent for treatment of failed mid-urethral sling procedures. Int Urogynecol J Pelvic Floor Dysfunct. 2010;21(12):1479–83.PubMedCrossRef
52.
Herschorn S, Radomski SB, Steele DJ. Early experience with intraurethral collagen injections for urinary incontinence. J Urol. 1992;148(6):1797–800.PubMed
53.
ter Meulen PH, Berghmans LC, Nieman FH, van Kerrebroeck PE. Effects of Macroplastique Implantation System for stress urinary incontinence and urethral hypermobility in women. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(2):177–83.PubMedCrossRef
54.
Cummings JM, Boullier JA, Parra RO. Transurethral collagen injections in the therapy of post-radical prostatectomy stress incontinence. J Urol. 1996;155(3):1011–3.PubMedCrossRef
Metadata
Title
Use of Injectable Urethral Bulking Agents in the Management of Stress Urinary Incontinence
Authors
Aisha Khalali Taylor
Elodi Dielubanza
John Hairston
Publication date
01-09-2011
Publisher
Current Science Inc.
Published in
Current Bladder Dysfunction Reports / Issue 3/2011
Print ISSN: 1931-7212
Electronic ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-011-0104-9

Other articles of this Issue 3/2011

Current Bladder Dysfunction Reports 3/2011 Go to the issue

ReviewPaper

Update on Neuromodulation

ReviewPaper

Clinically Relevant Terminology of the Female Lower Genitourinary Tract

ReviewPaper

Multiple Sclerosis and Voiding Dysfunction in Women

ReviewPaper

Bladder Pain Syndrome, Interstitial Cystitis, Painful Bladder Syndrome, and Hypersensitive Bladder Syndrome: New Nomenclature/New Guidelines

ReviewPaper

Current Concepts in Female Neurogenic Voiding Dysfunction

ReviewPaper

Robotics for Pelvic Reconstruction